Great News Quiltman , some serious sales made in the ODD Space , Table Below
Orphan drugs refer to the pharmaceuticals which are used for the diagnosis, prevention, and treatment of rare medical disorders. Rare diseases are a health condition which generally affects small number of people compared with other prevalent diseases in general population. It is estimated that globally around 6000-8000 rare diseases exist with new rare diseases being reported in medical literature regularly. As rare diseases have low prevalence and individually rare, collectively they affect around 6-8% of the population. These diseases include genetic disorders, rare cancers, infectious topical diseases, and degenerative diseases. Around 80% of the rare diseases are genetic in nature and therefore mainly affects children.The last few years have seen rapid influx in approval of orphan drugs which is mainly attributed to the restless efforts by scientists and rising awareness among population
Key Orphan Drug Sales 2022
Drug
Company
FDA Approval
Indication
2021 Sales
1 Keytruda
Merck
2014
melanoma, NSCLC, HNSCC, classical HL, primary mediastinal large B-cell lymphoma, urothelial carcinoma, CRC, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and TNBC.
US$ 17.18 Billion
2 Revlimid
Bristo Myers Squibb
2005
Multiple myeloma, Follicular Lymphoma, myelodysplastic syndromes, mantle cell lymphoma, marginal zonal lymphoma
US$ 12.8 Billion
3 Opdivo
Bristo Myers Squibb
2014
NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, HNSCC, urothelial carcinoma, CRC, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer.
US$ 7.52 Billion
4 Trikafta
Vertex Pharmaceutical
2019
Cystic Fibrosis
US$ 5.69 Billion
5 Imbruvica
AbbVie
2015
Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma
US$ 5.4 Billion
6 Hemlibra
Genentech
2017
Hemophilia A
US$ 2.35 Billion
7 Lynparza
AstraZeneca
2014
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
US$ 2 Billion
8 Vyndaqel
Pfizer
2019
Cardiomyopathy of Transthyretin-Mediated Amyloidosis
US$ 2 Billion
9 Darzalex
Janssen Biotech
2015
Multiple Myeloma
US$ 1.64 Billion
10 Soliris
Alexion Pharmaceuticals
2007
Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome, Myasthenia Gravis
US$ 1 Billion
11 Venclexta
Abbvie
2016
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
US$ 934 Million
12 Jakafi
Incyte Corporation
2011
Myelofibrosis
US$ 592 Million
- Forums
- ASX - By Stock
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
Great News Quiltman , some serious sales made in the ODD Space ,...
-
- There are more pages in this discussion • 560 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M |
Open | High | Low | Value | Volume |
19.0¢ | 19.5¢ | 19.0¢ | $58.40K | 305.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 115000 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 86074 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.190 |
8 | 156232 | 0.185 |
10 | 635662 | 0.180 |
10 | 482365 | 0.175 |
8 | 151233 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 86074 | 3 |
0.200 | 256824 | 3 |
0.205 | 113150 | 5 |
0.210 | 333355 | 8 |
0.215 | 266995 | 7 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
PAA (ASX) Chart |